HCA Forecast, price target & analysts
HCA Target price 2025 - Analyst rating & recommendation
HCA Classifications & Recommendation:
HCA Price Target
| Target Price | $501.84 |
| Price | $474.02 |
| Potential |
5.87%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target HCA 2026 .
The average HCA target price is $501.84.
This is
5.87%
register free of charge
$551.25
16.29%
register free of charge
$376.94
20.48%
register free of charge
|
|
| A rating was issued by 31 analysts: 18 Analysts recommend HCA to buy, 13 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the HCA stock has an average upside potential 2026 of
5.87%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 70.60 | 76.50 |
| 8.67% | 8.35% | |
| EBITDA Margin | 19.63% | 20.35% |
| 0.38% | 3.67% | |
| Net Margin | 8.16% | 8.38% |
| 1.11% | 2.72% |
26 Analysts have issued a sales forecast HCA 2025 . The average HCA sales estimate is
This results in the following potential growth metrics:
27 Analysts have issued an HCA EBITDA forecast 2025. The average HCA EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
27 HCA Analysts have issued a net profit forecast 2025. The average HCA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 22.00 | 27.88 |
| 16.03% | 26.73% | |
| P/E | 17.11 | |
| EV/Sales | 1.99 |
27 Analysts have issued a HCA forecast for earnings per share. The average HCA EPS is
This results in the following potential growth metrics and future valuations:
Current HCA Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho |
Locked
➜
Locked
|
Locked | Dec 18 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Dec 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Mizuho:
Locked
➜
Locked
|
Dec 18 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Dec 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 27 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
